Wells Fargo
DRMA icon

Wells Fargo’s Dermata Therapeutics DRMA Stock Holding History

Wells Fargo’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$2.16K – 7202
2025
Q1 		$2.16K Sell
200
-5
-2% -$61 ﹤0.01% 6147
2024
Q4 		$2.76K Hold
205
– – ﹤0.01% 6147
2024
Q3 		$3.35K Buy
205
+200
+4,000% +$3.98K ﹤0.01% 5993
2024
Q2 		$108 Hold
5
– – ﹤0.01% 6244
2024
Q1 		$289 Hold
5
– – ﹤0.01% 6412
2023
Q4 		$429 Hold
5
– – ﹤0.01% 6419
2023
Q3 		$744 Hold
5
– – ﹤0.01% 6269
2023
Q2 		$1.16K Sell
5
-5
-50% -$1.36K ﹤0.01% 6291
2023
Q1 		$1.97K Hold
10
– – ﹤0.01% 6226
2022
Q4 		$9.99K Hold
10
– – ﹤0.01% 5550
2022
Q3 		$13K Buy
10
+5
+100% +$7.8K ﹤0.01% 5571
2022
Q2 		$7K Hold
5
– – ﹤0.01% 5880
2022
Q1 		$14K Buy
+5
New +$17.1K ﹤0.01% 6147
2021
Q4 		– Hold
0
– – – 7316
2021
Q3 		– Hold
0
– – – 7042

Other funds holding DRMA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo's DRMA Position: Q2 2025 in Review

Wells Fargo sold out of Dermata Therapeutics (DRMA) in Q2 2025, closing a stake of 200 shares — an estimated $2.16K sold.

Wells Fargo first reported a position in DRMA in Q1 2022 and held it in 13 quarters. The position peaked at $14K in Q1 2022. 10 funds tracked by Wall St. Rank hold DRMA as of Q2 2025.

  • Wells Fargo reported no remaining Dermata Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wells Fargo sold 200 Dermata Therapeutics shares in Q2 2025, an estimated $2.16K.
  • Wells Fargo first reported a position in Dermata Therapeutics in Q1 2022 and held it in 13 quarters.
  • Wells Fargo's Dermata Therapeutics position peaked at $14K in Q1 2022.
  • 10 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2025.

Based on Wells Fargo's 13F filing for Q2 2025, filed 14 Aug 2025.